Related Experiment Video
Updated: Jun 11, 2025

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells
Published on: September 12, 2019
Role of Pyroptosis in Endometrial Cancer and Its Therapeutic Regulation
Abdullah Al Mamun1,2, Peiwu Geng1, Shuanghu Wang1
1Key Laboratory of Joint Diagnosis and Treatment of Chronic Liver Disease and Liver Cancer of Lishui, The Lishui Hospital of Wenzhou Medical University, The First Affiliated Hospital of Lishui University, Lishui People's Hospital, Lishui, Zhejiang, 323000, People's Republic of China.
Abstract:
Pyroptosis is an inflammatory cell death induced by inflammasomes that release several pro-inflammatory mediators such as interleukin-18 (IL-18) and interleukin-1β (IL-1β). Pyroptosis, a type of programmed cell death, has recently received increased interest both as a therapeutic and immunological mechanism. Numerous studies have provided substantial evidence supporting the involvement of inflammasomes and pyroptosis in a variety of pathological conditions including cancers, nerve damage, inflammatory diseases and metabolic conditions. Researchers have demonstrated that dysregulation of pyroptosis and inflammasomes contribute to the progression of endometriosis and gynecological malignancies. Current research also indicates that inflammasome and pyroptosis-dependent signaling pathways may further induce the progression of endometrial cancer (EC). More specifically, dysregulation of NLR family pyrin domain 3 (NLRP3) and caspase-1-dependent pyroptosis play a contributory role in the pathogenesis and development of EC. Therefore, pyroptosis-regulated protein gasdermin D (GSDMD) may be an independent prognostic biomarker for the detection of EC. This review presents the molecular mechanisms of pyroptosis-dependent signaling pathways and their contributory role and function in advancing EC. Moreover, this review offers new insights into potential future applications and innovative approaches in utilizing pyroptosis to develop effective anti-cancer therapies.
Insights
Pyroptosis, an inflammatory cell death, is implicated in endometrial cancer (EC) progression. Targeting pyroptosis pathways, particularly NLRP3 inflammasome and GSDMD, offers potential for novel EC therapies.
Area of Science:
- Immunology
- Cell Biology
- Oncology
Background:
- Pyroptosis is a pro-inflammatory programmed cell death pathway mediated by inflammasomes.
- Dysregulation of pyroptosis and inflammasomes is linked to various diseases, including cancers.
- Endometrial cancer (EC) progression is associated with aberrant inflammasome and pyroptosis signaling.
Purpose of the Study:
- To review the molecular mechanisms of pyroptosis in endometrial cancer (EC).
- To explore the role of pyroptosis-dependent pathways in EC pathogenesis and progression.
- To discuss the potential of pyroptosis as a therapeutic target for EC.
Main Methods:
- Literature review of studies on pyroptosis, inflammasomes, and endometrial cancer.
- Analysis of molecular mechanisms involving NLRP3 inflammasome, caspase-1, and GSDMD in EC.
- Synthesis of current research on pyroptosis-related signaling pathways in EC development.
Main Results:
- NLRP3 inflammasome and caspase-1-dependent pyroptosis contribute to EC pathogenesis.
- Pyroptosis-regulated protein gasdermin D (GSDMD) may serve as an independent prognostic biomarker for EC.
- Aberrant pyroptosis signaling pathways can drive the progression of EC.
Conclusions:
- Pyroptosis plays a significant role in the development and progression of endometrial cancer.
- Targeting pyroptosis pathways presents a promising avenue for developing novel anti-cancer therapies for EC.
- GSDMD is a potential biomarker for EC prognosis and warrants further investigation.
More Related Videos
Related Concept Videos
Mitogens and the Cell Cycle
Targeted Cancer Therapies
There are several types of targeted therapies against...

